Novartis licenses more ImmunoGen technology

Novartis (NVS) has licensed the exclusive right to use ImmunoGen's (IMGN) ADC technology to develop anti-cancer drugs.

This is the second time that Novartis has made such a move - under a 2010 agreement, the Swiss giant pays an upfront fee to ImmunoGen for each license, milestone payments worth as much as $200M, and any royalties on sales. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs